Workflow from Scientific Research

Treatment plan of UCPVax. UCPVax includes UCP2 and UCP4 pan-HLA-DR binding helper peptides derived from telomerase (hTERT) as previously described (Adotevi et al.41). Each helper peptide was emulsified in the adjuvant Montanide ISA-51 VG and injected subcutaneously. Patients received 6 weekly injections (priming) following by booster vaccinations for 8 weeks (boost) for a maximum of 12 months. Blood samples were collected for immune readouts as indicated (created withBioRender.com).

DOI